The secretion of tissue-type plasminogen activator (t-PA) from melanoma cells (Bowes) was investigated with or without monensin treatment. Monensin inhibited secretion of t-PA from the cells to the medium in a dose-and time-dependent manner. The inhibition was accompanied by an intracellular accumulation of t-PA. Electrophoretic enzymography of the cell homogenate showed the main lytic zone at 72 kDa, which reacted with the IgG of anti-t-PA.
to 35S-methionine-related protein.
The sugar chain of intracellular t-PA was analyzed with endoglycosidase H and N-glycanase, which reduced the molecular weight of t-PA by 4.5-10 kDa, indicating the intracellular presence of a high-mannose type sugar chain and a complex-type sugar chain of t-PA. t-PA secreted from the monensin-treated cells possesses a high-mannose type sugar chain only. Therefore, monensin alters the secretion of t-PA by abnormal glycosylation.
Plasminogen activator (PA), which is a serine enzyme, converts the inactive zymogen plasminogen to the active enzyme plasmin (27) . Plasmin digestion of fibrin is the primary action of the fibrinolytic system. Because PA has many biological functions, it has been investigated not only as a trigger enzyme for thrombolysis (fibrinolysis) but also as an important enzyme in the processes of ovulation (30), mammary development (22), tissue remodeling (36), and malignant transformation (24). PA can be immunologically classified into two types: urokinase-type PA (u-PA) (6, 15, 20) , which is produced in the urinary tract and is secreted into urine, and tissue-type PA (t-PA) (13, 16, 25, 26) which exists in the endothelium, in several organs including heart, ovary, and uterus, and in some malignant cells. Human melanoma cells (Bowes) also secrete large amounts of t-PA into conditioned medium (25). However, the mechanism of t-PA secretion from melanoma cells (Bowes) has been the subject of very little investigation.
Monensin, a monovalent cationic ionophore with high specificity for the sodium ion (2) , inhibits the secretion and intracellular transport of several glycoproteins (10, 11, 23, 31, 33) , and also alters sugar modification in the cell (14). Although t-H. Fukao, et al.
PA is a glycoprotein, the effect of monensin on modification of the t-PA molecule, as well as on the cellular secretion of t-PA, has not been investigated. Disruption of N-linked glycosylation of t-PA by tunicamycin treatment reduced the secretion of t-PA in chinese hamster ovary cells (8). The present study describes the intracellular transport mechanism of t-PA and the biochemical properties of intracellularly accumulated t-PA in the presence or absence of monensin, using cultured human melanoma cells (Bowes). MATERIALS 
AND METHODS

Materials
RESULTS
Effects of monensin on t-PA secretion. The effect of monensin on t-PA secretion was investigated in the two samples. In experiment A, where monensin still existed in the medium during the experimental period at the same concentration as during the pre-treatment, t-PA secretion from the cells to the medium was markedly inhibited (Fig. 1A) . In experiment B, where monensin was removed from the medium during the experimental period after pre-treatment of cells with monensin, t-PA secretion from the cells to the medium recovered gradually, although it was still inhibited in a dose-dependent manner (Fig. 1B) . On the contrary, intracellular PA activity was increased twofold by pre-treatment of the cells with monensin, and further accumulated in experiment A (Fig. 2A) trol cells. In the monensin treated cells, 20.7% of the 35S-methionine-related protein bound to anti-t-PA IgG. The incorporation of 35S-methionine into the whole cell did not change in the presence or absence of monensin. Therefore, the ratio of 3H-mannose-related glycoprotein to 35S-methionine-related protein was increased about 2.6-fold in the whole cell by the monensin treatment, and about 2.7-fold in the absorbed protein to anti-t-PA IgG-Sepharose. Thus, monensin treatment enhances the production of t-PA as a glycoprotein in melanoma cells (Bowes). 72 kDa in the control conditions. The endoglycosidase H treatment decreased the molecular weight of intracellular t-PA by 4.5 kDa and 6 kDa in control cells (lane 4) and in the monensin-treated cells (lane 5), respectively. The N-glycanase treatment decreased the molecular weight by 10 kDa in both cells (lanes 6 and 7). These results suggest that the high-mannose type sugar chain and the complex type sugar chain coexist in intracellualr t-PA. The content of the high-mannose type sugar chain increased in the monensin-treated group as compared with the control group. With the endoglycosidase H treatment, the extracellular t-PA did not show any molecular weight changes in control cells (lane 10), but endoglycosidase H treatment decreased the molecular weight by 9 kDa in the monensin-treated cells (lane 11). N-glycanase treatment decreased the molecular weight by 9 kDa in both control and monensintreated cells (lanes 12 and 13) . Therefore, t-PA secreted from the monensin-treated cells possesses only the high-mannose type sugar chain.
DISCUSSION
The enzymatic action of t-PA has been extensively studied and application of t-PA to thrombolytic therapy in acute myocardial infarction has been performed. The level of fibrinolytic activity under physiological conditions is determined by the t-PA released into circulating blood from the tissue and cells. The established cell line from melanoma cells [melanoma (Bowes)] has been used for the purification of t-PA because melanoma (Bowes) cells secrete large amounts of t-PA into tissue culture medium. However, the mode of secretion, as well as the intracellular distribution,
have not yet been investigated. Monensin, a monovalent carboxylic ionophore, abolishes transmembrane proton gradients (31) and inhibits the function of the Golgi apparatus (9, 31), which leads to intracellular accumulation.
The osmotic swelling of Golgi cisternae (23) may be due to disruption of ATP-dependent proton pumps situated on the Golgi membranes (32). In general, exocytic protein secretion from cells can be divided into two classes. The first involves a regulated secretion in which the rapid release of protein from storage granules is controlled by external stimuli. The other is a constitutive secretion, in which the export of newly synthesized proteins takes place without the need for stimulation by secretagogues (4). The mode of PA secretion in melanoma (Bowes) cells has not yet been analyzed. Monensin inhibited the secretion of t-PA from melanoma (Bowes) cells (Fig. 1) , which was accompanied intracellular accumulation of t-PA (Fig. 2) . However, melanoma (Bowes) cells increased the secre-tion of protein (Fig. 3) . Therefore, t-PA was regareded as a monensin-sensitive glycoprotein. To investigate the intracellular accumulation of t-PA, the distribution of t-PA in the cell organelles was investigated by ultracentrifugation in a discontinuous sucrose density gradient. The activity and antigen of t-PA were widely distributed from rough ER to the trans Golgi apparatus in the control cells (Fig. 4) . Monensin treatment markedly increased the activity and antigen of the intracellular t-PA. Tunicamycin treatment resulted in the accumulation of t-PA in the ER (8). These results indicate that N-linked glycosylation in t-PA molecule is important factor for the secretion.
When the sugar chain of t-PA was examined with 3H-mannose, 3H-mannoselabeled t-PA was widely distributed, and was increased markedly by monensin treatment (Fig. 5) . This is confirmed by the ratio of 3H-mannose labeled t-PA to 35S-methionine-labeled t-PA (Table 1) . That is, the ratio was increased from 0.214 of the control to 0.586 of the monensin treatment, indicating an increase in abnormal glycosylation in the cells.
The intracellular t-PA possesses both a high-mannose type and a complex type sugar chain, because endoglycosidase H and N-glycanase treatment reduced the molecular weight of t-PA. When melanoma (Bowes) cells were treated with monensin, the secretion of the complex type t-PA was disturbed and the cells secreted only the high-mannose type sugar chain t-PA. Therefore, monensin secretes t-PA as a glycoprotein with selectivity. Thus, monensin modifies the sugar chain of t-PA whose secretion was inhibited through the cell membrane. 
